Sign up for the Abwiz Bio Newsletter to get actionable advice and exclusive deals direct to your inbox.
Phospho-Stat3 (Tyr705) (B12) rabbit mAb FITC conjugate
Customers Also Viewed
|Description||Considered an oncogene, Stat3 is constitutively active in 70% of solid and hematological tumors, including leukemia, lymphoma, and multiple myeloma. The IL-6-Jak-Stat3 pathway can mediate cancer inflammation through both mutation of key regulatory genes and environmental stressors. Attempts at directly targeting Stat3 in cancer therapy have focused on the development of phosphopeptides and mimics that interact with the phospho-tyrosine-SH2 domain of Stat3 in an effort to destabilize active dimers and prevent DNA binding. Stat3 is primarily phosphorylated at Tyr705 upon activation of the Jak-Stat3 pathway. Secondary phosphorylation at Tyr727 at the C-terminus is thought to occur after Tyr705 phosphorylation. However, studies in melanoma have shown constitutive phosphorylation at Tyr727 that promotes survival of these cancerous cells.|
|Please Note||We are currently experiencing technical difficulties with our website that we hope to resolve soon. For order inquiries, please e-mail email@example.com. International shipping is available.|
|Validated Reactivity||Human, Mouse|
|Cross Reactivity||Predicted to work with mouse, rat and other homologues.|
|Immunogen||A synthetic phospho-peptide corresponding to residues surrounding Tyr705 of human phospho Stat3|
|Formulation||1X PBS, 0.09% NaN3, 0.2% BSA|
|Recommended Usage||For flow cytometric staining, the suggested use of this reagent is 5 µL per million cells or 5 µL per 100 µL of staining volume. It is recommended that the reagent be titrated for optimal performance for each application.|
|Pseudonyms||Signal transducer and activator of transcription 3, Acute-phase response factor, APRF|
|References||Avalle L, Pensa S, Regis G, Novelli F, and Poli V. (2012) JAK-STAT. 1: 65-72.
Yu H, Pardoll D, and Jove R. (2009) Nature Review Cancer. 9: 798-809.
Sakaguchi M, Oka M, Iwasaki T, Fukami Y, and Nishigori C. (2012) Journal of Investigative Dermatology. 132: 1877-1885.
Flow cytometric analysis of Jurkat cells secondary antibody only negative control (blue) or untreated (red) or treated with IFNa IL4 and pervanadate (green) using Phospho-Stat3 (Tyr705) antibody Stat3Y705 B12-FITC Cat. #1123.
Phospho-Stat3 (Tyr705) (B12) rabbit mAbCatalog#: 1121
Phospho-Stat3 (Tyr705) (B12) rabbit mAb PE conjugateCatalog#: 1122
Phospho-Stat3 (Tyr705) (B12) rabbit mAb APC conjugateCatalog#: 1124